

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Beijing Airdoc Technology Co., Ltd.**  
**北京鷹瞳科技發展股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2251)**

**RESIGNATION OF A SUPERVISOR  
AND  
PROPOSED APPOINTMENT OF A DIRECTOR AND A SUPERVISOR**

This announcement is made by Beijing Airdoc Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.51(2) and 13.51(1) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

**Resignation of a Supervisor**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby announces that Mr. WEI Yubo (魏宇博) (“**Mr. Wei**”) has tendered his resignation as a supervisor of the Company (the “**Supervisor**”) with effect from the date of this announcement due to internal transfer within the Group.

Mr. Wei has confirmed that he has no disagreement with the Company, the Board and the board of Supervisors of the Company (the “**Board of Supervisors**”) and that there are no other matters relating to his resignation that need to be brought to the attention of the Stock Exchange and the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to thank Mr. Wei for his valuable contributions to the Company during his tenure as a Supervisor.

**Proposed Appointment of a Director and a Supervisor**

The Board is pleased to announce that during its meeting held on May 26, 2025, it resolved to nominate Mr. Wei as a candidate for executive Director of the second session of the Board, and resolved to propose the appointment of Mr. Wei to the forthcoming

2024 annual general meeting of the Company (the “AGM”) for consideration and approval. The appointment of Mr. Wei as an executive Director will be effective upon the approval by the Shareholders at the AGM.

The Board is also pleased to announce that, Ms. Luo Yujie (羅玉潔) (“Ms. Luo”) was elected as an employee representative Supervisor at the meeting of the employee representatives of the Company. Ms. Luo was further elected as the chairman of the Board of Supervisors at the meeting of the Board of Supervisors held on May 26, 2025.

The biographical details of Mr. Wei and Ms. Luo are as follows:

**Mr. WEI Yubo (魏宇博)**, aged 45, joined the Group in April 2016 and has been serving as a Supervisor from December 2016 to May 2025. Mr. Wei is primarily responsible for overseeing the Group’s business operations and managing technical testing and medical quality control. Mr. Wei also serves as a supervisor in certain subsidiaries of the Company.

From July 2012 to April 2016, Mr. Wei served as an engineer of IGT Technology (Beijing) Co., Ltd. (IGT科技開發(北京)有限公司), where he was primarily responsible for software development and testing. From April 2006 to June 2012, Mr. Wei worked successively at Beyondsoft Technology Co., Ltd. (博彥科技股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 002649) and Microsoft, where he was mainly responsible for Mac Office Testing.

Mr. Wei received his bachelor’s degree in electronic information engineering from Jilin University (吉林大學) in the PRC in July 2004.

**Ms. Luo Yujie (羅玉潔)**, aged 40, joined the Group in April 2022 and currently serves as the head of internal audit of the Group. She is responsible for overseeing the Group’s internal audit and risk management.

Ms. Luo has over 18 years of experience in auditing and internal control. From June 2015 to April 2022, Ms. Luo joined Shimao Group Holdings Limited (世茂集團控股有限公司), a company whose shares are listed on the Stock Exchange (stock code: 813), as an assistant director of the audit department. From August 2006 to June 2015, Ms. Luo served as an audit manager at KPMG Huazhen LLP (Special Limited Partnership) (畢馬威華振會計師事務所(特殊普通合夥)).

Ms. Luo obtained a bachelor of economics degree in finance from Beijing Language and Culture University (北京語言大學) in July 2006. She was admitted as a member of the Chinese Institute of Certified Public Accountants (CICPA) in November 2009.

The term of office of Mr. Wei shall commence from the date of approval at the AGM until the expiry of the term of office of the second session of the Board. Mr. Wei shall be eligible for re-election upon the expiry of his term of office. The Company will enter into a three-year service contract with Mr. Wei upon approval at the AGM. Mr. Wei will not

receive remuneration in his capacity as a Director from the Company during his term of office. Pursuant to his service contract, Mr. Wei will be entitled to additional benefits (including without limitation the incentives under any equity incentive scheme to be adopted by the Company) at the Board's discretion. As of the date of this announcement, Mr. Wei held 42,693 H Shares of the Company.

The term of office of Ms. Luo shall commence from May 26, 2025 until the expiration of the term of office of the second session of the Board of Supervisors. She shall be eligible for re-election upon the expiry of her term of office. The Company will enter into a three-year service contract with Ms. Luo. Ms. Luo will not receive remuneration in her capacity as a Supervisor from the Company during her term of office. Pursuant to her service contract, Ms. Luo will be entitled to additional benefits (including without limitation the incentives under any equity incentive scheme to be adopted by the Company) at the Board's discretion. As of the date of this announcement, Ms. Luo held 4,140 H Shares of the Company.

Each of Mr. Wei and Ms. Luo did not hold any directorships in any listed companies in the past three years prior to the date of this announcement or have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company. Save as disclosed above, as of the date of this announcement, each of Mr. Wei and Ms. Luo did not hold any positions in the Company or any of its subsidiaries or have any interest in the securities of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)). Neither Mr. Wei nor Ms. Luo has been subject to any penalty or punishment imposed by the China Securities Regulatory Commission or any other relevant authorities or stock exchanges. Save as disclosed above, the Board is not aware of other information on the proposed appointment of Mr. Wei and Ms. Luo which shall be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters that need to be brought to the attention of the Shareholders.

A circular containing, among other matters, details of the proposed appointment of Mr. Wei, together with the notice of the AGM, will be dispatched to the Shareholders in due course.

By order of the Board  
**Beijing Airdoc Technology Co., Ltd.**  
**Mr. ZHANG Dalei**  
*Chairman of the Board*

Hong Kong, May 26, 2025

*As of the date of this announcement, the Board comprises Mr. ZHANG Dalei, Ms. WANG Lin, Dr. HE Chao and Mr. QIN Yong as executive Directors; and Dr. WU Yangfeng, Dr. HUANG Yanlin and Mr. NG Ho Yin Owen as independent non-executive Directors.*